<DOC>
	<DOC>NCT01114204</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared to IV iron sucrose for the treatment of iron deficiency anemia (IDA).</brief_summary>
	<brief_title>A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide, saccharated</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Key Inclusion Criteria include: 1. Males and females ≥18 years of age 2. Subjects with IDA 3. Subjects who have a history of unsatisfactory oral iron therapy or in whom oral iron cannot be used 4. Female subjects of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to screening and agree to remain on birth control until completion of participation in the study Key Exclusion Criteria include: 1. History of allergy to IV iron 2. Allergy to two or more classes of drugs 3. Subjects on dialysis or with an estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73m2 4. Female subjects who are pregnant, intend to become pregnant, are breastfeeding, within 2 weeks postpartum, or have a positive serum/urine pregnancy test 5. Hemoglobin ≤7.0 g/dL 6. Serum ferritin &gt;600 ng/mL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Iron deficiency anemia</keyword>
	<keyword>Feraheme</keyword>
	<keyword>ferumoxytol</keyword>
	<keyword>iron sucrose</keyword>
	<keyword>Venofer</keyword>
	<keyword>AUB</keyword>
	<keyword>cancer</keyword>
	<keyword>GI disorders</keyword>
	<keyword>postpartum anemia</keyword>
	<keyword>The treatment of iron deficiency anemia (IDA)</keyword>
</DOC>